Pharmacotherapy of inborn errors of metabolism illustrating challenges in orphan diseases
Related Experiment Video
Updated: Mar 25, 2026
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
1Department of Paediatrics, Centre for Rare Diseases, Hannover Medical School, Germany; Centre for Systems Neurosciences, Germany.
Abstract:
Orphan diseases (OD) have special challenges based on the rarity of the conditions. Mostly multicentre studies are required, controlled studies are difficult to perform. Based on the often chronic course of OD with slow progress the effect of therapeutic interventions is difficult to assess. Development and production of pharmaceutical substances for OD is difficult, time-consuming and sophisticated. Special incentives by the regulatory bodies like protocol assistance, long marketing exclusivity and reduced licencing fees encourage the development of orphan drugs. Inborn errors of metabolism (IEMs) due to enzyme or transporter deficiencies are taken as an example for OD. Accumulation of substrates proximal to the deficient enzyme during catabolic episodes leads to autointoxication with acute onset of symptoms. IEMs due to transporter deficiency usually have a more stable, chronic course. Therapeutic options are substrate reduction by diet or drugs, vitamin/cofactor supplementation, enzyme replacement, enzyme augmentation and transplantation of organs or cells. Phenylketonuria (PKU) is the prototype of an IEM which can be successfully treated by diet. The outcome of hepatorenal tyrosinaemia type 1 was revolutionarized by substrate reduction using nitisinone (NTBC) which was discovered by chance. Lysosomal storage diseases are examples where enzyme replacement therapy is successful. Enzyme augmentation can be achieved in some IEM-patients with a mild phenotype (residual enzyme activity) by chaperones which stabilize the enzyme. Organ transplantation is an option in those patients who cannot be managed by drugs and/or diet. Bone marrow transplantation is successful in some patients where CNS-involvement occurs. The CNS cannot be reached by enzyme replacement therapy (blood-brain barrier). While safety and efficacy of drugs for OD have been demonstrated pre-marketing, post-marketing surveys are often necessary to include more patients.
Insights
Orphan diseases (OD) present unique challenges, but regulatory incentives foster orphan drug development. Therapeutic strategies for inborn errors of metabolism (IEMs) include diet, enzyme replacement, and transplantation.
Area of Science:
- Rare disease research
- Pharmacology
- Metabolic disorders
Background:
- Orphan diseases (OD) are rare, posing challenges for multicenter studies and therapeutic assessment due to chronic progression.
- Developing pharmaceuticals for OD is complex and time-consuming, necessitating regulatory support.
- Inborn errors of metabolism (IEMs) exemplify OD, with substrate accumulation causing acute symptoms in enzyme deficiencies or chronic issues in transporter deficiencies.
Purpose of the Study:
- To review the challenges and therapeutic strategies for orphan diseases, using inborn errors of metabolism as a case study.
- To highlight the role of regulatory incentives in promoting orphan drug development.
- To discuss various treatment modalities for IEMs, including diet, enzyme replacement, and transplantation.
Main Methods:
- Literature review of orphan diseases and inborn errors of metabolism.
- Analysis of therapeutic options for IEMs, including substrate reduction, enzyme replacement, and transplantation.
- Discussion of regulatory incentives for orphan drug development.
Main Results:
- Therapeutic options for IEMs include diet, substrate reduction (e.g., nitisinone for hepatorenal tyrosinaemia type 1), vitamin supplementation, enzyme replacement therapy (e.g., for lysosomal storage diseases), enzyme augmentation (e.g., using chaperones), and organ/cell transplantation.
- Phenylketonuria (PKU) is effectively managed by diet.
- Enzyme replacement therapy is limited for central nervous system (CNS) involvement due to the blood-brain barrier, where bone marrow transplantation may be effective.
- Post-marketing surveillance is crucial for assessing safety and efficacy in broader patient populations.
Conclusions:
- Orphan diseases require specialized approaches, with diverse therapeutic strategies available for inborn errors of metabolism.
- Regulatory incentives are vital for encouraging the development of orphan drugs.
- While significant progress has been made, ongoing research and post-marketing studies are essential for optimizing patient outcomes in orphan diseases.
More Related Videos
09:54Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Related Concept Videos
01:20Inborn Errors of Metabolism
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:27Pharmacogenetics of Drug Metabolism: Overview
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase